arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Protara Therapeutics, Inc.

TARA
$4.12 ▲ +0.02 (+0.49%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
54 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Weak
Bearish
auto_awesome

Analytical Summary

Protara Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $237.1M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC -8.6%
FCF / Share $-0.37
Trailing P/E
Price / Book 1.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-17.78M
↓ -49.3%
FCF / Share Free cash flow per share
$-0.37
↓ -2.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
23
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 54 quarters